Sequentially measured effect of diffrent esketamine infusion rate combined with low dose dexmedetomidine on sevoflurane MACBAR

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072743

Enrollment

Unknown

Registered

2023-06-25

Start date

2023-06-25

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecological operation

Interventions

Group E0D0 (blank):The dose of sevoflurane is increased or decreased according to the patient's peeling response

E0D0.3 group (dexmedetomidine 0.3µg/kg.h):The dose of sevoflurane is increased or decreased according to the patient's peeling response

E0.3D0.3 (Esketamine 0.3mg/kg.h+ dexmedetomidine 0.3µg/kg.h):The dose of sevoflurane is increased or decreased according to the patient's peeling response

E0.4D0.3 (Esketamine 0.4mg/kg.h+ dexmedetomidine 0.3µg/kg.h):The dose of sevoflurane is increased or decreased according to the patient's peeling response

E0.5D0.3 (Esketamine 0.5mg/kg.h+ dexmedetomidine 0.3µg/kg.h):The dose of sevoflurane is increased or decreased according to the patient's peeling response

Eligibility

Sex/Gender

Female

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) 150 patients were selected to undergo gynecological lower abdominal surgery under general anesthesia with tracheal intubation; (2) Age 20-55 years old; (3)BMI 18.5 ~ 24.9kg/m2; (4)ASA ? or ? grade, (5) mouth opening =2.5cm, chin distance =6.5cm, head and neck motion normal, Mallampati ? or ? grade.

Exclusion criteria

Exclusion criteria: (1)BMI=25kg/m2; (2) difficult airway; (3) Airway hyperreactive disease within 1 month; (4) Allergic history of benzodiazepines, non-depolarizing muscle relaxants, and opioids; (5) have myasthenia gravis, neurological or psychiatric diseases; (6) Cardiovascular and brain diseases and recent use of drugs that have an impact on the cardiovascular system; (7) A history of drug abuse or alcoholism; (8) Recent use of analgesic drugs; (9) Patients with severe anemia, coagulation dysfunction, etc.

Design outcomes

Primary

Measure	Time frame
Peeling reaction;	—

Secondary

Measure	Time frame
mean arterial pressure;heart rate;	—

Countries

China

Contacts

Public ContactJian Qichang

Boai Hospital Of Zhongshan,Affiliated to Southern Medical University

2679754006@qq.com+86 189 2815 2703

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026